title: Control of bovine uterine prostaglandin F2 alpha release in vitro.
abstract: Prostaglandin F2 alpha (PGF2 alpha) release from the uterus causes luteolysis in ruminants, and oxytocin is thought to be a regulator of this release. In the present study, we have examined the mechanisms involved in oxytocin stimulation of PGF2 alpha secretion by bovine endometrium in vitro. Endometrial tissue explants, obtained from heifers at Day 19 or 20 (n = 3) and Day 0 (estrus, n = 5) of the estrous cycle, were incubated for 2 h and 6 h, and PGF2 alpha concentration in the medium was determined by radioimmunoassay (RIA). Basal PGF2 alpha release increased for up to 6 h and was significantly stimulated after 2 h of incubation with 100 microU and 1000 microU of oxytocin at Day 0 but not at Day 19 or 20. Secretion of PGF2 alpha was not affected by cholera toxin (10 ng/ml) or the cyclic nucleotide analogs dibutyryl cyclic adenosine 3',5'-monophosphate and dibutyryl cyclic guanosine 3',5'-monophosphate at a concentration of 1 mM. A protein kinase A inhibitor (500 microM) had no effect on the oxytocin-induced release of PGF2 alpha. Both the phorbol ester, 12-myristate-13-acetate (100 mM), and the non-phorbol stimulator of protein kinase C, 1-octanoyl-2-acetylglycerol (500 microM), significantly stimulated PGF2 alpha secretion to the same extent as oxytocin. Neither basal nor stimulated PGF2 alpha release was affected by the calcium ionophore A23187 (0.1-5.0 microM). However, PGF2 alpha secretion was sensitive to cycloheximide (1 microgram/ml) suggesting that protein synthesis may be involved. In conclusion, these data suggest that the stimulation of PGF2 alpha by oxytocin is via the protein kinase C effector pathway.
authors.affiliation: Centre de Recherche en Reproduction, Faculté de Médecine Véterinaire, Université de Montréal, Québec, Canada.
authors.forename: M
authors.initials: M
authors.lastname: LaFrance
authors.forename: A K
authors.initials: AK
authors.lastname: Goff
mesh_terms: D000818:Animals; D001095:Arachidonic Acids / Q000494:pharmacology; D003994:Bucladesine / Q000494:pharmacology; D000001:Calcimycin / Q000494:pharmacology; D002273:Carcinogens / Q000494:pharmacology; D002417:Cattle; D002772:Cholera Toxin / Q000494:pharmacology; D003513:Cycloheximide / Q000494:pharmacology; D003995:Dibutyryl Cyclic GMP / Q000494:pharmacology; D004075:Diglycerides / Q000494:pharmacology; D015237:Dinoprost / Q000378:metabolism*; D004717:Endometrium / Q000378:metabolism; D005260:Female; D009712:Nucleotides, Cyclic / Q000378:metabolism / Q000502:physiology; D010121:Oxytocin / Q000494:pharmacology / Q000502:physiology; D010703:Phorbol Esters / Q000494:pharmacology; D047428:Protein Kinase Inhibitors; D013755:Tetradecanoylphorbol Acetate / Q000494:pharmacology; D014599:Uterus / Q000378:metabolism* / Q000502:physiology
chemical_list: D001095:Arachidonic Acids; D002273:Carcinogens; D004075:Diglycerides; D009712:Nucleotides, Cyclic; D010703:Phorbol Esters; D047428:Protein Kinase Inhibitors; C008876:phorbol-12,13-didecanoate; D003995:Dibutyryl Cyclic GMP; D000001:Calcimycin; D010121:Oxytocin; D003994:Bucladesine; C038237:1-oleoyl-2-acetylglycerol; D002772:Cholera Toxin; D003513:Cycloheximide; D015237:Dinoprost; D013755:Tetradecanoylphorbol Acetate